Guardant sells blood tests that detect and monitor cancer.
Guardant Health, Inc. (GH) is expected to report earnings on Wednesday, October 28, 2026, after the close. Estimated release time 16:09 ET. Consensus EPS estimate is $-0.28.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | FY2026 Q2 | $-0.76 | $-0.90 | -18.1% | $334.98M |
| 2026-05-07 | FY2026 Q1 | $-0.81 | $-0.85 | -5.5% | $301.67M |
| 2026-02-19 | FY2025 Q4 | $-0.77 | $-0.90 | -17.4% | $281.27M |
| 2025-10-29 | FY2025 Q3 | $-0.48 | $-0.39 | +18.7% | $265.20M |
| 2025-07-30 | FY2025 Q2 | $-0.52 | $-0.44 | +15.4% | $232.09M |
| 2025-04-30 | FY2025 Q1 | $-0.61 | $-0.49 | +19.7% | $203.47M |
| 2025-02-20 | FY2024 Q4 | $-0.75 | $-0.62 | +17.3% | $201.81M |
| 2024-11-06 | FY2024 Q3 | $-0.55 | $-0.45 | +18.2% | $191.48M |
GH has beaten consensus EPS in 5 of its last 8 reported quarters.
Highlights from GH's Jul 30 report: EPS of -$0.90 — a sharp miss vs the -$0.76 estimate (-18%); revenue of $335M — a beat vs the $314M consensus (+7%). Focus now shifts to Shield launch and reimbursement.
See GH on the live calendar →